All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2019-D-1536
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework; Draft Guidance for Industry; Availability
Documents
4
Comments
33
Key Dates
Comment Period OpensJun 20, 2019
Comment Period ClosesAug 21, 2019
Documents
Comment Statistics
Total Comments
33
Keywords
2018-551
CDER
Guidance for Industry
Opioid Analgesic Drugs
Considerations for
Benefit-Risk Assessment Framework
Open
Data from Regulations.gov